Is clopidogrel superior to aspirin in secondary prevention of vascular disease? by Algra, Ale & van Gijn, Jan
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
Commentary
Is clopidogrel superior to aspirin in secondary prevention of
vascular disease?
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Abstract
The cornerstone in clinical evidence of the relative efficacy of thienopyridines (clopidogrel,
ticlopidine) versus aspirin in the secondary prevention of vascular disease is the Clopidogrel
versus Aspirin in Patients at Risk of Ischaemic Events trial. This trial showed a modest
benefit in the reduction of vascular events by clopidogrel. The results differed according to
qualifying disorder: myocardial infarction, –3.7%; ischaemic stroke, +7.3%; and peripheral
arterial disease, +23.8% (P = 0.042). Similar results were found for ticlopidine after brain
ischaemia. The safety of clopidogrel appears to be similar to that of aspirin and better than
that of ticlopidine. However, the recent report of thrombotic thrombocytopenic purpura in
association with clopidogrel causes concern.
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Introduction
A nice bottle of Graves arrived at our offices in early
August 2000. The Dutch branch of Sanofi-Synthelabo
sent this wine to collaborators of the Clopidogrel versus
Aspirin in Patients at Risk of Ischaemic Events (CAPRIE)
trial [1] to celebrate the regulation of reimbursement for
clopidogrel in the Netherlands on 26 July. The official indi-
cation for this novel antiplatelet drug reads: ‘secondary
prevention in patients with atherosclerotic disease and
proven aspirin sensitivity’. Sanofi-Synthelabo appealed
against the limitation to patients intolerant to aspirin, but
lost the lawsuit [2].
CAPRIE: clopidogrel versus aspirin
What is the background of this legal quarrel? The corner-
stone is clinical evidence from the CAPRIE trial, a ran-
domised, blinded, international study [1]. Clopidogrel
(75 mg daily) and aspirin (325 mg daily) were compared in
the prevention of the composite outcome event ‘vascular
death, nonfatal stroke or nonfatal myocardial infarction’.
Clopidogrel reduced the annual risk of such a vascular
event from 5.83 to 5.32% in comparison with aspirin, cor-
responding to a relative risk reduction (RRR) of 8.7%. The
95% confidence interval just kept clear of the neutral value
and ranged from 0.3 to 16.5%. The design of the studyCurrent Controlled Trials in Cardiovascular Medicine    Vol 1 No 3 Algra and  van Gijn
was based on the paradigm prevalent in the early 1990s:
all clinical presentations of atherosclerotic disease should
be regarded as different manifestations of a single disor-
der of the arterial vascular tree. The data of the CAPRIE
trial do not necessarily support this paradigm, because the
RRR values of the three diagnostic strata (each with over
6000 patients) differed considerably: –3.7% for myocar-
dial infarction, +7.3% for ischaemic stroke, and 23.8% for
peripheral arterial disease (P = 0.042). A similar difference
between different categories of atherosclerotic disease
had been observed by the AntiPlatelet Trialists’ Collabora-
tion [3]. The RRR values achieved by aspirin (compared
with placebo) ranged from 18% for cerebral ischaemia to
35% for unstable angina.
All thienopyridines versus aspirin
Clopidogrel is a thienopyridine chemically related to the
already available ticlopidine. Both thienopyridines block
the activation of platelets by selective and irreversible in-
hibition of binding of ADP to its platelet receptor. A recent
review by the Cochrane Library reviewed the effects of
this class of drugs [4,5]. Four trials on the comparison of
thienopyridines with aspirin, with a total of 22,656
patients, were identified. Most information came from the
CAPRIE trial (72% of the outcome events) and virtually all
other data originated from the Ticlopidine Aspirin Stroke
Study [6]. This latter trial enrolled patients with a recent
transient ischaemic attack (TIA) or minor ischaemic stroke
and found a 6% RRR (95% confidence interval, –7% to
+17%) of vascular events [7], an effect quite similar to
that observed in the CAPRIE stroke stratum.
Side effects
One of the reasons for developing clopidogrel was the risk
of neutropenia with ticlopidine use (neutropenia occurred
in 2.3% of the ticlopidine treated patients in the Ticlopi-
dine Aspirin Stroke Study [6]) necessitating monitoring of
white blood cell counts. This side effect occurred far less
frequently in the CAPRIE trial, which closely monitored for
these events; no differences in this regard were observed
between clopidogrel and aspirin [1]. With respect to other
side effects, more skin rash and diarrhoea were reported
with clopidogrel whereas aspirin use led to more upper
gastrointestinal discomfort, gastrointestinal haemorrhage
and abnormalities of the liver function [1]. The New
England Journal of Medicine posted an expedited publi-
cation on its website earlier this year on 11 cases of
thrombotic thrombocytopenic purpura [8], which was trig-
gered by similar adverse effects from ticlopidine. The rate
of thrombocytopenic purpura associated with clopidogrel
(3.7 per million) appears to be similar to what might be
expected in the community [9]. The recent publicity on
this life threatening side effect is, however, likely to
increase the awareness of clinicians of clopidogrel
related thrombocytopenic purpura, which might lead to
more such reports.
Which outcome measure?
Another issue is whether the primary outcome of the
CAPRIE trial should consist of the composition of several
types of vascular events. Albers [10] recently argued that
stroke trials should use stroke as an outcome, rather than
all vascular events. His main argument was of a statistical
nature: because the most important effects in a stroke trial
are obtained in the prevention of stroke, the inclusion of
non-stroke vascular events would dilute such an effect.
Sample size requirements for future trials would thus be
less stringent. We disagree with Albers’ reasoning on two
points. Most important, this approach departs from the
patient’s perspective. A patient presenting with vascular
disease, either cerebrovascular, cardiac, or peripheral, has
a high risk of future vascular events anywhere in the arter-
ial tree. Indeed, new events tend to be most frequent in
the presenting organ during the first years after presenta-
tion, but the whole vascular bed is later at risk. Because a
patient does not want to be harmed by either a stroke or a
myocardial infarction, protection against any such event
should be offered. Trials should thus be designed in such
a way that they can address this point of view by means of
a composite vascular outcome event. One may even
argue, from the patient’s perspective, to include major
bleeding complications as one of the most important side
effects in the evaluation of antithrombotic treatment [11].
A second objection to Albers’ reasoning is that sample
size requirements need not necessarily be advantageous
with a stricter outcome definition. The benefit gained by a
(expected) higher treatment effect may be offset by a
smaller number of outcome events. We thus consider the
choice of the primary outcome event of the CAPRIE trial
appropriate for use in clinical practice. Restricted outcome
definitions, which always come free with the use of com-
posite events, may nevertheless be useful in unravelling
pathophysiological mechanisms.
Costs and the market
Would clopidogrel be cost effective in secondary preven-
tion? Hankey and Warlow calculated that it would cost
approximately US$33,000 to avoid one stroke in sec-
ondary stroke prevention with clopidogrel, whereas aspirin
would cost only US$1400 in the same situation [12].
Meanwhile, Sanofi-Synthelabo and Bristol-Meyers adver-
tise their drug and are sometimes overenthusiastic about
clopidogrel. One advertisement stated that clopidogrel
reduced the number of ischaemic events by 26% com-
pared with aspirin treatment [13]. This misleading number
represented a relative efficacy, on comparison with an
imaginary placebo group, derived from data of the
AntiPlatelet Trialists’ Collaboration.
New research
At least one new study with clopidogrel as a secondary pre-
vention drug is about to start. The combination of 75 mg
clopidogrel and 75 mg aspirin daily will be compared withc
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clopidogrel only in the MATCH trial (ie Management of
ATherothrombosis with Clopidogrel in High-risk patients
with recent TIA or ischaemic stroke). The primary outcome
of this trial will be the same composite event used in the
CAPRIE trial extended with rehospitalisation for acute
ischaemic events. The study aims to enrol 7600 patients
with ischaemic brain disease. The atherosclerosis paradigm
has clearly lost its attractiveness in the new millennium. The
MATCH study will also not answer the question whether it
is useful to add clopidogrel to aspirin, but will answer only
the reverse question. More data are available on the efficacy
of aspirin, the current standard in patients with ischaemic
brain disease, than on the efficacy of clopidogrel [1,14,15].
Conclusions
In summary, clopidogrel appears to be somewhat more
effective than aspirin if one is willing to accept the unitary
atherosclerosis paradigm. The gain, however, is modest:
about 200 patients should use clopidogrel rather than
aspirin for 1 year to prevent just one vascular event. If one is
sceptical about the atherosclerosis paradigm, there is little
reason to use clopidogrel after myocardial infarction and
good grounds to replace aspirin by clopidogrel in peripheral
arterial disease. The data are not convincing after ischaemic
stroke, and cost considerations would tip the balance in
favour of aspirin. The conservative attitude of the Dutch
authorities in their regulation of reimbursement of clopido-
grel is understandable. We have to await the results of
studies on the combined efficacy of clopidogrel and aspirin
for a reassessment of the position of clopidogrel.
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